# A Study to Evaluate 9MW2821 Versus Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer

> **NCT06196736** · PHASE3 · RECRUITING · sponsor: **Mabwell (Shanghai) Bioscience Co., Ltd.** · enrollment: 432 (estimated)

## Conditions studied

- Advanced Urothelial Carcinoma

## Interventions

- **DRUG:** 9MW2821
- **DRUG:** Chemotherapy

## Key facts

- **NCT ID:** NCT06196736
- **Lead sponsor:** Mabwell (Shanghai) Bioscience Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-12-29
- **Primary completion:** 2026-09
- **Final completion:** 2027-07
- **Target enrollment:** 432 (ESTIMATED)
- **Last updated:** 2025-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06196736

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06196736, "A Study to Evaluate 9MW2821 Versus Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT06196736. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*